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SIGNIFICANCE OF IMMUNOHISTOCHEMISTRY IN ACCURATE 
CHARACTERIZATION OF MALIGNANT TUMORS 
Zubair Ahmed, Najamul Sahar Azad, Yasmeen Bhurgari, Rashida Ahmed, Naila Kayani, 
Shahid Pervez, Sheema Hasan 
Department of Pathology & Microbiology, The Aga Khan University Hospital, Stadium Road, Karachi, Pakistan 
Background: To determine in a large series of surgical biopsies the role and significance of 
immunohistochemistry in the adequate and accurate characterization of malignant tumors. 
Methods: A retrospective study of 20,000 consecutive surgical biopsies reported in the Section of 
Histopathology, AKU in 2003. Data was obtained by retrieving the filed surgical biopsy reports in 
the section. Results and Conclusions: Out of the 20,000 biopsies, 6534 (32.67%) were 
neoplastic. 4726 neoplasms (72.33%) were malignant, and 1808 (27.67%) were benign. 
Immunohistochemistry was performed on 29.49% of malignant tumors, and 4.97% of benign 
tumors. Immunos were performed on only 2.82% of routine squamous cell carcinomas and 
adenocarcinomas of various organs, and in only 1.9% of infiltrating breast carcinomas, the 
commonest malignant tumors in females. In contrast, immunos were performed on 97.12% of 
non-Hodgkin’s lymphomas, 97.94% of Hodgkin’s lymphomas, 98.09% of malignant spindle cell 
neoplasms, 87.96% of small round blue cell tumors of childhood, 87.30% of neuroendocrine 
neoplasms, and 84.37% cases of malignant melanomas. In addition, immunos were performed on 
all cases of malignant undifferentiated neoplasms and were able to resolve the issue in over 89% 
of such cases. Immunos were also performed on 54.74% of metastatic tumors. Lymph nodes were 
the commonest organs on which immunos were performed i.e. 96.50% of lymph node tumors, 
followed by CNS and renal neoplasms with 33.01% and 25.92% respectively.  
Key Words: Malignant tumours, Karachi, Immunochemistry 
INTRODUCTION 
The histologic diagnosis of cancer and the 
categorization of the proper tumor type is essential 
for the adequate treatment of malignant tumors. 
Histologic subtyping with the help of 
immunohistochemical characterization of tumors has 
resulted in a level of distinction between diagnoses 
which was not previously possible. In addition to 
substantiating the diagnosis of malignancy, this 
subtyping provides information which is essential in 
guiding therapy. The distinction between 
histologically similar tumors is often critical as 
therapeutic options often differ.1  
Immunohistochemistry has emerged as the 
most valuable adjunct to Hematoxylin and Eosin 
(H&E) staining in diagnostic histopathology.2 No 
other method during the past fifty years has had such 
a major impact on histopathology.3 This technique 
has equipped the histopathologist with the tools 
needed to tackle the most common diagnostic 
problems in tumor pathology especially the 
characterization of the undifferentiated or poorly 
differentiated malignant tumors, whether primary or 
metastatic.4-6 The impact of immunohistochemistry 
has been enhanced by the large number of good 
quality antibodies that are available commercially 
and improvements in antigen retrieval techniques.7 
No modern histopathology laboratory can 
hope to function without adequate 
immunohistochemistry facilities. The section of 
Histopathology at the Aga Khan University Hospital 
(AKUH) has state of the art immunohistochemistry 
facilities and a large, diverse and ever-expanding 
panel of antibodies is available. This has proved 
invaluable in the development of our section as the 
major referral center especially for tumor pathology 
in Pakistan. 
The aim of our study was to determine in a 
large series of surgical biopsies, the role and 
significance of immunohistochemistry in the 
adequate and accurate characterization of malignant 
tumors. 
MATERIAL AND METHODS 
A retrospective study of 20,000 consecutive surgical 
biopsies reported in the section of Histopathology, 
AKUH in 2003. Data was obtained by retrieving the 
filed surgical biopsy reports in the section.  
The immunohistochemistry technique used 
is a combination of immunocytochemistry, which 
attaches the tracer to the specific antigen within the 
tissue sections, and standard enzyme histochemistry 
which visualizes the tracer for bright field or electron 
microscopy.    
Several procedures are available. The two 
most commonly used are the peroxidase 
antiperoxidase immune complex method and the 
biotin avidin immunoenzymatic technique. In the 
latter, the high affinity of avidin for biotin is used to 
couple the peroxidase label to the primary antibody.  
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We use the envision system. This is a two 
step immunohistochemistry staining technique. This 
is based on an HRP labeled polymer against which 
primary antibodies produced in mice react well. 
These primary mouse antibodies are supplied by the 
user. The combination then reacts with the antigens 
in paraffin embedded tissues cryostat tissues etc. 
Tissues processed in a variety of fixatives may be 
used. The procedure used is described in table 1. 
It is of utmost importance to use fresh 
solutions; make sure antibody is not expired, run 
appropriate controls for every batch of each antibody. 
It is recommended that immunos are done on all 
cases of Non-Hodgkin’s and Hodgkin’s lymphoma, 
all cases of undifferentiated malignant neoplasms, all 
sarcomas for further characterization, in metastatic 
tumors, sometimes even in benign lesions for 
adequate characterization and on cytology cell 
blocks.  
RESULTS 
Out of the 20,000 consecutive biopsies, 6534 
(32.67%) were neoplastic and 13,466 (67.33%) were 
non-neoplastic. Of the neoplastic lesions 4726 
(72.33%) were malignant, while 1808 (27.67%) were 
benign. Immunohistochemistry was performed on 
29.49% of malignant tumors.(Table-1) 
Very few (2.82%) of the routine squamous 
cell carcinomas, adenocarcinomas of various organs 
required immunohistochemistry. These carcinomas 
comprised a large chunk of malignant tumors. There 
were 1665 cases of such ordinary types of carcinoma 
and another 736 infiltrating carcinomas of the breast. 
Together, these 2401 tumors comprised 50.80% of all 
malignant tumors. But immunohistochemistry was 
required in only a tiny percentage of these cases. 
Infiltrating carcinomas of the breast, which comprise 
the commonest malignant tumors in females required 
immunohistochemistry in only 1.9% cases. On the 
other hand, immunohistochemistry was performed on 
97.12% of Non Hodgkin’s lymphomas, 97.94% of 
Hodgkin’s lymphomas, 98.09% of malignant spindle 
cell neoplasms, 87.96% of small round blue cell 
tumors of childhood, 87.30% of neuroendocrine 
neoplasms, and 84.37% cases of malignant 
melanomas. (Table-2) 
Malignant undifferentiated neoplasms 
required immunohistochemistry in all cases (n=213). 
Immunohistochemistry allowed accurate diagnosis in 
190 of these cases (89.20%). In less than 11% such 
cases, immunohistochemistry was unhelpful. 
Metastatic tumors (n=316) comprised 6.69% of all 
malignant tumor. Immunohistochemistry was 
performed in 173 out of 316 metastatic tumors or 
54.74%. 
Table-1: Distribution of cases on the basis of 

















Malignant 4726 1394 29.49% 
Benign 1808 73 4.97% 
All Tumors 6534 1467 22.45% 
Non-neoplastic 13,466 59 0.44% 
All Lesions 20,000 1526 7.63% 
Table 2: Distribution of cases on the basis of 
morphology 
Morphology 
Non-Hodgkin’s lymphoma 382 371 97.12% 
Hodgkin’s lymphoma 97 95 97.94% 
Malignant Spindle cell 
neoplasms 157 154 98.09% 
Small round blue cell tumors 108 95 87.96% 
Neuroendocrine tumors. 63 55 87.30% 
Malignant melanomas 32 27 84.37% 
Table 3:  Distribution of cases on the basis of site 
of origin 
Organ / Tissue Total Number 
Number 











Lymph nodes 372 359 (96.50 %) 
CNS 212 70 (33.01 %) 
Kidney 54 14 (25.92 %) 
Testis 44 11 (25 %) 
Bone 137 27 (19.71 %) 
Liver 60 7 (11.66 %) 
Ovary 242 26 (10.74 %) 
Thyroid 69 6 (8.69 %) 
Salivary Gland 71 6 (8.45 %) 
Skin * 143 11 (7.69 %) 
U. Bladder 129 8 (6.20 %) 
Vascular 142 8 (5.63 %) 
Prostate 126 5 (3.97 %) 
*squamous cell carcinomas not included 
In 73 of these 173 cases (23.74%), CK 7 and 
CK 20 antibodies were utilized to give accurate 
information about the site of the primary tumor. 
Certain neoplasms like gastrointestinal stromal tumor 
(GIST), anaplastic large cell (Ki 1) lymphoma 
(ALCL), mesothelioma etc. required 
immunohistochemistry in all cases. Among specific 
organs, immunohistochemistry was performed on 
96.50% of lymph node neoplasms, followed by CNS 
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neoplasms (33.01%) and renal neoplasms (25.92%). 
(Table-3). 
DISCUSSION 
The optimal treatment of patients with cancer 
depends on establishing accurate diagnoses by using 
a complex combination of clinical and 
histopathological data. In some instances, this task is 
difficult or impossible because of atypical clinical 
presentation or histopathology. 
With advances in the treatment of cancers, 
surgeons and oncologists now demand accurate 
characterization of malignant tumors. And with 
histopathology also developing spectacularly as a 
science, it has now become possible in the large 
majority of cases to accurately subtype malignant 
tumors histologically. Immunohistochemistry is the 
most important tool that has made this possible. Its 
advantages include its remarkable sensitivity and 
specificity, its applicability to routinely processed, 
formalin fixed material, and compatibility to most 
common fixatives.8  
Recognizing the importance of 
immunohistochemistry in tumor pathology, the 
section of Histopathology, AKU has developed 
excellent immunohistochemistry facilities, which are 
provided in cases which require 
immunohistochemistry, without any additional 
charge from the patient, despite the use of one to 
more than ten antibodies used per case, with an 
average of four to five.  
However, there is no over-dependence on 
immunohistochemistry. Immunos were performed on 
only 29.49% of all malignant tumors where accurate 
diagnosis and characterization of tumors was not 
possible. In Pakistan, where histopathology is still 
evolving as a science and most centers lack 
immunohistochemistry facilities, it is imperative that 
a major referral center like AKU should utilize this 
technique in order to provide accurate diagnosis. A 
study conducted by Ahmed et al9 showed that lack of 
immunohistochemistry facilities can result in 
significant differences in diagnosis in difficult cases. 
As shown in our results, 
immunohistochemistry is performed in all malignant 
undifferentiated neoplasms and the use of extensive 
panels of antibodies in such cases allows accurate 
histologic diagnosis in more than 89% cases. 
Immunohistochemistry is performed in all cases of 
suspected Non-Hodgkin’s and Hodgkin’s lymphoma. 
The few cases (Table 2) in which it was not 
performed were those cases in which only slides were 
sent for second opinion and no blocks were available. 
All Non-Hodgkin’s lymphomas are phenotyped into 
B or T cell types according to the WHO / REAL 
classification of lymphoid neoplasms.10,11 Similarly 
Hodgkin’s lymphomas are confirmed by 
immunohistochemistry. 
In some cases it may be difficult to 
differentiate Hodgkin’s lymphomas from anaplastic 
large cell (ki 1) lymphoma (ALCL) or diffuse large B 
cell lymphoma. ALCL can only be diagnosed by 
immunohistochemistry. In all suspected cases of 
Non-Hodgkin’s and Hodgkin’s lymphomas, a panel 
of antibodies including LCA (CD45), CD 20 and CD 
79 (Pan B markers), CD 3 and UCHL 1 (Pan T 
markers), CD15 (GAA) and CD 30 (ki 1) are used. In 
suspected cases of ALCL, Epithelial membrane 
antigen (EMA) and ALK protein an also used.12,13 
We are now diagnosing a large number of cases of 
ALCL which in the past may have been 
misdiagnosed as Hodgkin’s lymphoma or Diffuse 
Large B cell lymphoma.   
Antibodies such as bel-2 and CD 10 can 
distinguish between reactive follicular hyperplasia 
and follicular lymphoma in difficult cases.14,15 There 
are prognostic and therapeutic differences between B 
and T Non-Hodgkin’s Lymphomas as well as 
Hodgkin’s lymphoma which make 
immunohistological characterization very important. 
Immunohistochemistry is also performed on most 
cases of malignant spindle cell neoplasms (soft tissue 
sarcomas) for their accurate characterization (Table 
2). The few cases in which immunos were not 
performed were those in which only slides were 
received or external blocks which showed marked 
processing artifact. On the basis of 
immunohistochemistry, soft tissue sarcomas can be 
accurately classified as fibrosarcomas, 
leiomyosarcomas, malignant peripheral nerve sheath 
tumors etc. The specific types of soft tissue sarcomas 
have prognostic and therapeutic difference which 
makes their accurate characterization very important. 
Also, the diversity of these tumors, their 
differentiation along several lines, and the difficulties 
often faced in their differential diagnosis with benign 
pseudosarcomatous lesions and non-mesenchymal 
malignant tumors makes their accurate typing with 
immunohistochemistry very important.2  
Gastrointestinal stromal tumors (GISTs), 
distinctive type of stromal tumors occurring in the 
GIT, must be distinguished from other mescenchymal 
tumors arising in the GIT. Immunohistochemistry is 
essential in the diagnosis of these neoplasms. 
The CD117 (c-kit) is a proto-oncogene 
which encodes a transmembrane tyrosine kinase 
receptor is normally expressed by the interstitial cells 
of Cajal in GIT. In GISTs, a c-kit mutation occurs 
and is thought to be the direct cause of the tumor.16 
CD 117 is positive in 85-100% cases of GISTs17 and 
this positivity requires to be demonstrated for the 
patient to receive the new effective treatment i.e. STI 
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571.18 With the use of this antibody in all suspected 
cases of GIST, we are now diagnosing these tumors 
with increasing frequency. These tumors in the past 
would have been characterized as smooth muscle or 
nerve sheath tumors. 
Similarly immunohistochemistry is 
performed in the overwhelming majority of small 
round blue cell tumors of childhood (Table 2). The 
few cases in which immunos were not performed 
included lesions such as retinoblastoma, 
nephroblastoma (Wilm’s tumor) etc. However, 
immunos are essential in differentiating between 
rhabdomyosarcoma, ewing’s sarcoma/primitive 
neuroectodermal tumor (PNET), lymphoma etc. In 
few other cases, immunos were not performed for the 
same reasons outlined above for other tumors. 
Neuroendocrine neoplasms comprise 
another diverse category which often present 
difficulties in diagnosis and also need to be 
accurately classified for prognostic and therapeutic 
reasons. Again, immunos were performed in a large 
majority of these cases in the form of a panel of 
antibodies including S-100 protein, Neuron specific 
enolase (NSE), chromogranin, synaptophysin and 
Neurofilament resulting in their accurate diagnosis 
(Table 2). 
Malignant melanomas, in most cases, are 
also confirmed by immunohistochemistry by using a 
panel of antibodies i.e. cytokeratins (negative in 
melanoma), S100 profein, vimentin and HMB 45 
(positive in melanoma). HMB 45 is a highly specific 
marker for melanoma.19
Immunohistochemistry is essential for the 
diagnosis of malignant mesothelioma of the pleura 
and to differentiate if from metastatic lung 
adenocarcinoma. We perform immunos on all pleural 
biopsies with malignant neoplasms using a panel of 
antibodies, Calretinin-Thrombomodulin-Cytokeratin 
5/6 (positive in mesothelioma, negative in 
adenocarcinoma) and Ber EP4 (negative in 
mesothelioma, positive in adenocarcinoma).20-22
Similarly, immunohistochemistry is almost always 
performed in other biphasic neoplasms such as 
synovial sarcoma for confirmation by employing 
antibodies such as EMA, cytokeratins, bcl-2 and 
CD99 (MIC2).2, 23, 24  
As shown in the results, very tiny 
percentages of ordinary carcinomas of various organs 
(e.g. Skin, esophagus, lungs, stomach, colorectum, 
endometrium etc) needed immunohistochemistry for 
confirmation (only less well differentiated cases) and 
similar was the case with infiltrating ductal 
carcinomas of breast which required immunos only 
when there was very little material or crushed 
material in trucut biopsy specimens and when there 
was need to exclude malignant lymphoma in such 
small specimens. So although these non-specific 
carcinomas of various organs (including breast) 
comprised a large chunk of malignant tumors, 
immunos were required in very few cases. 
According to the results, 
immunohistochemistry was performed on 54.74% of 
metastatic tumors. esp. tumors in lymph nodes, brain, 
liver etc to rule out primary neoplasms of these 
organs. In lymph nodes, cytokeratins together with 
lymphoid markers were used. In the brain, 
cytokeratins were used together with glial fibrillary 
acidic protein (GFAP) to rule out a high grade 
astrocytoma.25 In the liver, cytokeratins CAM 5.2 and 
AE1/AE3 were used in poorly differentiated cases. 
These two antibodies are of great value in 
distinguishing between a primary hepatocellular 
carcinoma and metastatic carcinoma in difficult cases 
as hepatocellular carcinoma is positive for CAM 5.2 
and negative for AE1/AE3, while metastatic 
carcinomas to liver are positive to both markers.26 In 
23.74% of metastatic tumors, CK7 and CK20 were 
used especially in cases of metastases occurring in 
omentum, mesentery etc. These antibodies often 
allowed us to predict the site of origin of the primary 
tumor since specific tumors are  either positive or 
negative to one or both these markers.4 CK7 and CK 
20, together with Prostate Specific Antigen (PSA) are 
also very useful in cases of poorly differentiated 
carcinoma of bladder and prostate where it cannot  be 
determined histologically whether the tumor is of 
bladder or prostatic origin. Urothelial carcinomas of 
bladder are CK7 and CK20 positive, and PSA 
negative, while the opposite is true for prostatic 
adenocarcinoma. In spinal metastases, we use PSA to 
conform that a metastatic adenocarcinoma represents 
a primary from the prostates.27
Table 3 shows the numbers and percentages 
of malignant tumors in specific organs on which 
immunohistochemistry is performed. Not 
surprisingly, lymph nodes are at the top of the list 
owing to the fact that immunos are performed in 
almost all cases of Non-Hodgkin’s and Hodgkin’s 
lymphomas. Tumors of the CNS are next due to the 
diversity of CNS neoplasms and the common 
occurrence of metastases in the CNS. More 
surprising is the fact that renal neoplasms are number 
three on the list, but it must be kept in mind that these 
include not only renal cell carcinomas, but other 
tumors as well. Other organs on which immunos are 
commonly performed include testis, bone, liver etc. 
As shown in the results, 
immunohistochemistry was also performed on 4.97% 
of benign tumors. These were those tumors which 
proved difficult to characterize accurately by H&E 
alone. Immunohistochemistry was also performed on 
0.44% of non-neoplastic cases. These were those 
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cases on which H&E could not prove conclusively 
whether they were neoplastic or not. 
The accurate characterization of neoplastic 
lesions, both malignant and benign, is also important 
from an academic view point. Being a major referral 
and research center for Histopathology in Pakistan, 
we need to have a complete and accurate data base of 
all neoplasms for research and academic purposes, 
and for our data to be acceptable internationally. 
Histopathology has now advanced to a stage where 
accurate characterization of most neoplasms is 
possible and should be attempted. 
Immunohistochemistry is the most valuable tool 
available to us for this purpose. If we do not update 
ourselves according to new techniques, we will be 
left far behind. Yet another transformation in 
histopathology is now occurring which is the 
application of molecular techniques to histopathology 
specimens. We must welcome these and adopt them 
but with a firm realization that all these are 
invaluable adjuncts to meticulous gross and 
microscopic examination, but cannot replace them. 
CONCLUSION 
Immunohistochemistry has emerged as the most 
valuable adjunct to routine H&E staining for accurate 
characterization of malignant neoplasms, esp in 
difficult and challenging cases. The accurate typing 
of malignant as well as benign tumors is important 
from diagnostic, prognostic, therapeutic, academic 
and research viewpoints, and immunohistochemistry 
is the main tool which has enabled the 
histopathologist to achieve this goal. The process is 
not cost-effective for all laboratories especially those 
in smaller cities, therefore it is suggested that better 
referral laboratory services should be available to 
give population coverage.     
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